Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT00808678
Collaborator
(none)
90
1
2
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
90 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date
:
Dec 1, 2008
Actual Primary Completion Date
:
Jan 1, 2009
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 1 ABT-143 capsules 20/135 mg |
Drug: ABT-143
once, see arm description for more information
|
Active Comparator: 2 ABT-335 135 mg and rosuvastatin 20 mg |
Drug: ABT-335
once, see arm description for more information
Drug: rosuvastatin
once, see arm description for more detail
|
Outcome Measures
Primary Outcome Measures
- To determine the safety and tolerability of ABT-143 vs (ABT-335 + rosuvastatin) in healthy adults [7 days]
- To determine the pharmacokinetic profile(s) for ABt-143 vs. (ABT-335 + rosuvastatin) in healthy adults [7 days]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
A condition of general good health
-
BMI 19 to 29
Exclusion Criteria:
-
Currently enrolled in another clinical study
-
Females who are pregnant or breast-feeding
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Site Reference ID/Investigator# 14762 | Orlando | Florida | United States | 32809 |
Sponsors and Collaborators
- AstraZeneca
Investigators
- Study Director: Torbjörn Lundström, MD, AstraZeneca
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00808678
Other Study ID Numbers:
- M10-662
First Posted:
Dec 16, 2008
Last Update Posted:
Sep 28, 2012
Last Verified:
Sep 1, 2012
Keywords provided by AstraZeneca
Additional relevant MeSH terms: